Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ZSP1601

Phase 2Small molecule

GGuangdong Raynovent Biotech Co., Ltd

ZSP1601 is one of 34 small molecule programs targeting Hepatitis. It is currently in Phase 2.

1

Indications

3

Total Trials

1

Active Trials

33

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

HepatitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

43 competitors in Hepatitis

#DrugCompanyPhaseTrials

Medrol

Sovaldi

Viread

Tyzeka

Glucophage

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Singulair

OOrganon and Co

Epivir

GGlaxo Dba Glaxosmithkline

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Cellcept

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Hepatitis

NCT05692492

Clinical

Trials by Indication[1]

Non-Alcoholic Steatohepatitis1 trial

Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Completed·GGuangdong Raynovent Biotech Co., Ltd·Phase 1/2·NCT04140123·37 enrolled

Adult1 trial

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics

Completed·GGuangdong Zhongsheng Pharmaceutical Co., Ltd.·Phase 1·NCT03392779·94 enrolled

Hepatitis1 trial

A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)

Active, not recruiting·GGuangdong Raynovent Biotech Co., Ltd·Phase 2·NCT05692492·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ZSP1601. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZSP1601 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZSP1601. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangdong Raynovent Biotech Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGuangdong Raynovent Biotech Co., Ltd

Related News